<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766465</url>
  </required_header>
  <id_info>
    <org_study_id>BMT CTN 1503</org_study_id>
    <secondary_id>1U01HL128568-01</secondary_id>
    <nct_id>NCT02766465</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)</brief_title>
  <acronym>STRIDE2</acronym>
  <official_title>A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN 1503)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial that will compare survival and sickle related outcomes in&#xD;
      adolescents and young adults with severe sickle cell disease after bone marrow&#xD;
      transplantation and standard of care. The primary outcome is 2-year overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective phase II multi-center trial of hematopoietic stem cell transplantation&#xD;
      or standard of care based on availability of HLA-matched related or unrelated donor after&#xD;
      confirmation of clinical eligibility. In order to minimize bias assignment to either&#xD;
      treatment arm, clinical eligibility to both treatment arms are similar and donor availability&#xD;
      is not known at referral. HLA typing and donor search is initiated upon confirmation of&#xD;
      clinical eligibility for the study. Additionally, all analyses of primary and secondary&#xD;
      endpoints will follow the Intent-to-Treat principle to address potential bias introduced by&#xD;
      participants with donors not proceeding to transplantation or those without a matched donor&#xD;
      receiving transplantation with less well-matched donors.&#xD;
&#xD;
      The primary outcome is 2-year overall survival. Our hypothesis is that patients who receive&#xD;
      bone marrow transplantation will experience early deaths but that this will plateau by 2&#xD;
      years after transplantation. Patients who receive standard of care will not experience early&#xD;
      death but will succumb to their disease at a rate much higher than the general population.&#xD;
      Therefore, the goal of the study is to establish that the difference in the proportion of&#xD;
      patients surviving is not significantly more than 15% lower in the donor arm at 2-years after&#xD;
      assignment to treatment arm.&#xD;
&#xD;
      Secondary endpoints will compare changes in sickle cell disease related events (pulmonary&#xD;
      hypertension, cerebrovascular events, renal function, avascular necrosis, leg ulcer) and&#xD;
      functional outcomes [6-minute walk distance (6MWD), health-related quality of life, cardiac&#xD;
      function, pulmonary function, and mean pain intensity as assessed by a multidimensional&#xD;
      electronic pain diary] from baseline to 2-years after assignment to treatment arms.&#xD;
&#xD;
      Additionally for patients assigned to the donor arm and expected to undergo transplantation,&#xD;
      hematopoietic recovery, graft rejection, acute and chronic graft-versus-host disease, other&#xD;
      significant transplant-related complications and disease-free survival will be reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are enrolled without a known donor. All patients have 180 days from confirmation of eligibility to confirm a donor. Patients with a donor will be assigned to the Donor Arm and receive HCT; patients without a donor will be assigned to the no donor arm and continue receiving standard of care for their SCD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 Years</time_frame>
    <description>OS will be compared between treatment arms using a point-wise comparison at 2-years, and the survival curves will be estimated using the Kaplan Meier product limit estimator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Sickle Cell Disease (SCD) related events</measure>
    <time_frame>2 Years</time_frame>
    <description>Examination of the occurrence of the SCD-related events will be performed. Exact logistic regression will be used to estimate an odds ratio of each of these events between treatment groups, assuming that at least one event occurs on study in each of the treatment groups, controlling for other patient related characteristics and individual history of the event of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Intensity</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Mean pain intensity assessed by an electronic pain diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>The 6-minute walk distance (6MWD) test will be used to assess exercise capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Cardiac function will be assessed by the change from baseline in Tricuspid regurgitant jet velocity (TRJV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Pulmonary function will be assessed by the change from baseline in Forced Expiratory Volume 1 second (FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Renal function will be assessed through measurements of albuminuria (urine-albumin creatinine ratio) and serum creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL)</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>HRQoL assessed using the NIH's PROMIS 57 instrument.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Donor Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donor Arm patients will undergo hematopoietic cell transplant. Patients with a matched unrelated donor will receive a bone marrow transplant (unless PBSC graft is pre-approved per section 2.5.1 using a preparative regimen with Busulfan, Fludarabine and rabbit ATG. Patients with an HLA-identical sibling donor can receive a transplant using one of three regimens:&#xD;
A. Busulfan, Fludarabine, and rabbit ATG using a bone marrow graft (preferred regimen) B. Alemtuzumab/TBI 300 cGy using a peripheral blood graft C. Alemtuzumab, fludarabine, melphalan using a bone marrow graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-Donor Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No-donor arm patients will continue with standard of care per their SCD physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>A:&#xD;
Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>A:&#xD;
Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2).&#xD;
C:&#xD;
Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-ATG</intervention_name>
    <description>A:&#xD;
r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg).</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Rabbit antithymocyte globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplant</intervention_name>
    <description>A,B,C:&#xD;
Day 0 is the day of transplantation.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Bone Marrow Transplant; BMT; HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>A:&#xD;
Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.&#xD;
C:&#xD;
Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Prograf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>A:&#xD;
Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2.&#xD;
C:&#xD;
Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Continue to receive standard of care treatment per patient's SCD physician.</description>
    <arm_group_label>No-Donor Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>B:&#xD;
Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3&#xD;
C:&#xD;
Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>Total Body Irradiation 300 cGY on Day -2</description>
    <arm_group_label>Donor Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ &gt;50%</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>C:&#xD;
Melphalan 140 mg/m2 IV dose will be given on Day -3</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF 5 μg/kg/day continue until neutrophil engraftment.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Granulocyte colony-stimulating factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 15 and &lt; 41 years&#xD;
&#xD;
          2. Severe sickle cell disease [Hemoglobin SS (Hb SS), Hemoglobin SC (Hb SC) or Hemoglobin&#xD;
             SBeta thalassemia (Hb Sβ) genotype] with at least 1 of the following manifestations&#xD;
             (a-e):&#xD;
&#xD;
               1. Clinically significant neurologic event (stroke) or any neurological deficit&#xD;
                  lasting &gt; 24 hours;&#xD;
&#xD;
               2. History of two or more episodes of acute chest syndrome (ACS) in the 2-year&#xD;
                  period preceding enrollment despite the institution of supportive care measures&#xD;
                  (i.e. asthma therapy);&#xD;
&#xD;
               3. An average of three or more pain crises per year in the 2-year period preceding&#xD;
                  enrollment (required intravenous pain management in the outpatient or inpatient&#xD;
                  hospital setting). Clinical documentation of pain management in the inpatient or&#xD;
                  outpatient setting is required.&#xD;
&#xD;
               4. Administration of regular RBC transfusion therapy, defined as receiving 8 or more&#xD;
                  transfusion events per year (in the 12 months before enrollment) to prevent&#xD;
                  vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest&#xD;
                  syndrome)&#xD;
&#xD;
               5. An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥&#xD;
                  2.7 m/sec.&#xD;
&#xD;
               6. Ongoing high impact chronic pain on a majority of days per month for ≥ 6 months&#xD;
                  as defined as ONE or more of the following: Chronic pain without contributory SCD&#xD;
                  complications, OR Mixed pain type in which chronic pain is occurring at site(s)&#xD;
                  (arms, back, chest, or abdominal pain) unrelated to any sites associated with&#xD;
                  Contributory SCD complications (e.g. leg ulcers and/or avascular necrosis).&#xD;
&#xD;
             i. High impact chronic pain is identified as those reporting &quot;severe interference&quot;&#xD;
             with life activities OR &quot;usually or always&quot; experiencing a limitation of their life or&#xD;
             work activities including household chores. (See guidelines for identifying HICP in&#xD;
             the BMT CTN 1503 Manual of Procedures) ii. Contributory SCD complications are defined&#xD;
             as clinical signs (e.g. presence of leg ulcers) or clinical assessments (e.g. imaging&#xD;
             confirmation of splenic infarct or avascular necrosis). Chronic pain attributed solely&#xD;
             to contributory SCD complications is excluded.&#xD;
&#xD;
          3. Adequate physical function as measured by all of the following:&#xD;
&#xD;
               1. Karnofsky/Lansky performance score ≥ 60&#xD;
&#xD;
               2. Cardiac function: Left ventricular ejection fraction (LVEF) &gt; 40%; or LV&#xD;
                  shortening fraction &gt; 26% by cardiac echocardiogram or by Multi Gated Acquisition&#xD;
                  Scan (MUGA).&#xD;
&#xD;
               3. Pulmonary function:&#xD;
&#xD;
             a. Pulse oximetry with a baseline O2 saturation of ≥ 85% b. Diffusing capacity of the&#xD;
             lung for carbon monoxide (DLCO) &gt; 40% (corrected for hemoglobin) d. Renal function:&#xD;
             Serum creatinine ≤ 1.5 x the upper limit of normal for age as per local laboratory and&#xD;
             24 hour urine creatinine clearance &gt;70 mL/min; or GFR &gt; 70 mL/min/1.73 m2 by&#xD;
             radionuclide Glomerular Filtration Rate (GFR).&#xD;
&#xD;
             e. Hepatic function:&#xD;
&#xD;
               1. Serum conjugated (direct) bilirubin &lt; 2x upper limit of normal for age as per&#xD;
                  local laboratory. Participants are not excluded if the serum conjugated (direct)&#xD;
                  bilirubin is &gt;2x the upper limit of normal for age as per local laboratory and:&#xD;
                  There is evidence of a hyperhemolytic reaction after a recent RBC transfusion, OR&#xD;
                  there is evidence of moderate direct hyperbilirubinemia defined as direct serum&#xD;
                  bilirubin &lt; 5 times ULN and not caused by underlying hepatic diseasePatients&#xD;
&#xD;
               2. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 5 times&#xD;
                  upper limit of normal as per local laboratory.&#xD;
&#xD;
        Additional inclusion required for donor arm participants to proceed with transplant&#xD;
&#xD;
          1. Liver MRI (≤ 90 days prior to initiation of transplant conditioning) to document&#xD;
             hepatic iron content is required for participants who are currently receiving ≥8&#xD;
             packed red blood cell transfusions for ≥1 year or have received ≥20 packed red blood&#xD;
             cell transfusions (cumulative). Participants who have hepatic iron content ≥7 mg Fe/ g&#xD;
             liver dry weight by liver MRI must have a liver biopsy and histological&#xD;
             examination/documentation of the absence of cirrhosis, bridging fibrosis and active&#xD;
             hepatitis (≤ 90 days prior to initiation of transplant conditioning).&#xD;
&#xD;
          2. Lack of clinical or radiologic evidence of a recent neurologic event (such as stroke&#xD;
             or transient ischemic attack) by Cerebral MRI/MRA within 30 days prior to initiating&#xD;
             transplant conditioning. Subjects with clinical or radiologic evidence of a recent&#xD;
             neurologic event will be deferred for ≥ 6 months with repeat cerebral MRI/MRA to&#xD;
             ensure stabilization of the neurologic event prior to proceeding to transplantation&#xD;
&#xD;
          3. Documentation of participant's willingness to use approved contraception method until&#xD;
             discontinuation of all immunosuppressive medications is to be documented in the&#xD;
             medical record corresponding with the consent conference.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HLA typing with a donor search prior to referral (consultation with HCT physician).&#xD;
&#xD;
               1. If a subject has had HLA typing and a related donor search that did not identify&#xD;
                  a suitably matched relative (i.e., sibling) at any time, and also did not have an&#xD;
                  unrelated donor search, the patient will be considered eligible.&#xD;
&#xD;
               2. If a subject has had HLA typing and a related donor search that did not identify&#xD;
                  a suitably matched relative (i.e., sibling) at any time and had an unrelated&#xD;
                  donor search that did not identify a suitably matched unrelated donor ≥ 1 year&#xD;
                  prior to enrollment, the patient will be considered eligible.&#xD;
&#xD;
               3. If a subject has had HLA typing with no related donor search and had an unrelated&#xD;
                  donor search that did not identify a suitably matched unrelated donor ≥ 1 year&#xD;
                  prior to enrollment, the patient will be considered eligible.&#xD;
&#xD;
               4. Subjects with a known HLA-identical sibling or HLA-matched unrelated donor are&#xD;
                  excluded&#xD;
&#xD;
          2. Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.&#xD;
&#xD;
          3. Seropositivity for HIV.&#xD;
&#xD;
          4. Previous HCT or solid organ transplant.&#xD;
&#xD;
          5. Participation in a clinical trial in which the patient received an investigational&#xD;
             drug or device must be discontinued at enrollment.&#xD;
&#xD;
          6. A history of substance abuse as defined by version IV of the Diagnostic &amp; Statistical&#xD;
             Manual of Mental Disorders (DSM IV).&#xD;
&#xD;
          7. Demonstrated lack of compliance with prior medical care as determined by referring&#xD;
             physician.&#xD;
&#xD;
          8. Pregnant or breast feeding females.&#xD;
&#xD;
          9. Inability to receive HCT due to alloimmunization, defined as the inability to receive&#xD;
             packed red blood cell (pRBC) transfusion therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Eapen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Benioff Children's Hospital at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Gainsville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation for Sickle Cell Research/Florida Sickle Inc.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center/Albert Einstein School of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Brooklyn Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Young Adults</keyword>
  <keyword>Phase II Trial</keyword>
  <keyword>Hematopoietic Cell Transplantation (HCT)</keyword>
  <keyword>Human Leukocyte Antigen (HLA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Within 6 months of official study closure at participating sites.</ipd_time_frame>
    <ipd_access_criteria>Available to the public</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/home/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02766465/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

